EP0870757A3 — Fluoro-substituted adamantane derivatives
Assigned to Pfizer Inc · Expires 2000-06-07 · 26y expired
What this patent protects
The invention relates to fluoro-substituted adamantane derivatives of the formula and to pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , and R 4 are as defined herein. The invention also relates to methods of treating neurological disorders, such as memory…
USPTO Abstract
The invention relates to fluoro-substituted adamantane derivatives of the formula and to pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , and R 4 are as defined herein. The invention also relates to methods of treating neurological disorders, such as memory loss and Parkinson's disease, and bacterial and viral infections, through administration of a therapeutically effective amount of a compound of formula I. The invention also relates to a method of increasing the metabolic stability of an adamantane-containing pharmaceutical compound by incorporating a fluoro substituent on at least one bridge-head carbon of the adamantyl group of said adamantane-containing pharmaceutical compound.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.